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Summary:  
 
Addictions are highly prevalent in bipolar disorder and greatly impact on clinical 
outcomes. In this editorial, we review the evidence that addictions are a key 
challenge in bipolar disorder, examine putative neurobiological mechanisms, and 
reflect on the limited clinical trial evidence base with suggestions for treatment 
strategies and further developments.   
 
Editorial: 
 
Bipolar disorder is one of the most challenging mental health disorders to assess 
and treat and a key challenge is the very high rates of addiction co-morbidities 
experienced by people with bipolar disorder. The increased prevalence of addictions 
in bipolar disorder is demonstrated by the recent United States National 
Epidemiologic Survey on Alcohol and Related Conditions which found that that 
people with bipolar I disorder have a 5.8 times increased lifetime risk of a substance 
use disorder diagnosis according to Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition criteria. This risk was still 2.3 times increased even after 
adjusting for other psychiatric co-morbidities (1). Studies in the United Kingdom also 
reflect the increased risk of addictions in bipolar disorder with 48% and 44% of 
people with bipolar disorder experiencing a lifetime history of alcohol and substance 
abuse respectively (2). Bipolar disorder has one of the highest rates of cigarette 
smoking of any mental health disorder and the lowest rate of smoking cessation (3). 
Increased rates of behavioral addictions, such as gambling disorder (4), have also 
been identified in bipolar disorder and approximately 1 in 10 people with bipolar 
disorder may have a moderate to severe lifetime risk of problem gambling (4). 
Addiction co-morbidity in bipolar disorder is important as it greatly impacts on clinical 
outcomes. For example, addiction co-morbidity in bipolar disorder is associated with 
more severe manic episodes, and increased risks of violence, suicide and relapse 
(5, 6). Despite their greater needs and increased risk, people with bipolar disorder 
and addiction co-morbidity often struggle to access secondary mental health 
services (7). 
 
Why are addictions so prevalent in bipolar disorder? 
 
The association between bipolar disorder and addictions raises the question: why 
are people with bipolar disorder at increased risk of addictions? There are several 
potential mechanisms. The first is that people with bipolar disorder “self-medicate” 
with alcohol or drugs to alleviate mood episodes. However only 25% of people with 
bipolar disorder increase their use of alcohol during a manic episode and most don’t 
change their use during a depressive episode (8). Indeed, people with bipolar 
disorder and addiction co-morbidities are no different to people with substance use 
disorder in experiencing increased substance sensitivity or sensation seeking, and in 
using substances to achieve a sense of euphoria or to alleviate mood and anxiety 
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symptoms irrespective of current mood episode. They also report similar motivations 
for substance use as the general population (9).  
 
The second potential mechanism is a shared neurobiology between bipolar disorder 
and addictions which means that people with bipolar disorder are at risk of 
addictions. Indeed, the prospective Zurich cohort study showed that manic 
symptoms or a diagnosis of bipolar II disorder was associated with a greatly 
increased risk of developing alcohol or benzodiazepine dependence over twenty 
years (10). Certainly there is evidence that young men who report high rates of 
hypomanic symptoms, and may be at risk of developing bipolar disorder, experience 
similar low level behavioral responses to alcohol as is found in those with a family 
history of alcohol dependence (11). Addiction co-morbidities in bipolar disorder are 
likely to be mediated by the involvement of a number of neurotransmitter systems. 
Much of the focus of addiction research has been on the dopamine neurotransmitter 
system and it is likely that vulnerability to addictions in bipolar disorder may be 
mediated, at least in part, through dopaminergic dysregulation. However, the 
evidence for this is limited by a lack of studies of the dopamine system in people with 
bipolar disorder and addiction comorbidity (12). Anxiety disorders are also highly 
prevalent in bipolar disorder and so there is also the possibility that people with 
bipolar disorder use alcohol or other substances to alleviate anxiety symptoms 
perhaps generated by GABA-A receptor dysregulation previously reported in anxiety 
disorders (13).   
 
Treatment approaches 
 
How to do we best treat people with bipolar disorder and co-morbid addictions? The 
first step is to ensure that co-morbid addictions are adequately identified in people 
with bipolar disorder. National Institute for Health and Care Excellence guidelines 
recommend that all patients who disclose substance use are asked about quantity, 
frequency and pattern of use, route of administration and duration of current level of 
use (14). It is also important to establish whether criteria for substance dependence 
is met as this will greatly influence clinical management (14). We would suggest that 
a history of behavioural addictions such as gambling, sexual and shopping 
addictions is also taken. Frequent re-assessment of substance use and behavioural 
addictions is recommended especially following a change in mental state (15). Once 
addiction co-morbidity has been identified the intensity of intervention will depend on 
the severity of the problem identified and resources available locally, but joint 
working with expert addictions services is recommended to achieve the best 
outcomes (7). It is important to note that addiction services are rarely commissioned 
to provide psychiatric care and so secondary care mental health services should 
lead treatment and people with bipolar disorder should not be excluded from these 
services because of addiction co-morbidity (7). Clinicians should also develop care 
plans that consider the potential for greater mood instability, higher risks of self-
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harm, and poorer medication adherence found in people with bipolar disorder with 
addictions co-morbidities.   
 
Pharmacological management 
 
The pharmacological management of bipolar disorder with addiction co-morbidities is 
complicated by a lack of good quality, placebo controlled, randomized control trials 
(RCTs). This may partly be due to pharmaceutical industry sponsored trials 
excluding people with bipolar disorder and co-morbid addictions. The evidence that 
does exist is based on a relatively small number of RCTs which typically assess the 
effects of interventions in less than thirty participants over a twelve-week period. 
Several RCT’s have investigated the effects of mood stabilizers on substance use 
and mood scores. Although we are not aware of any studies that have examined the 
effect of lithium in people with bipolar disorder and alcohol dependence, a large 
multicenter trial of lithium in alcohol dependent people with a history of depression 
found no improvement in alcohol consumption or mood scores (16). Another study 
found that sodium valproate in addition to lithium and psychosocial interventions 
improved alcohol consumption but not mood scores in people with bipolar disorder 
and alcohol dependence (17). Turning to bipolar disorder with substance use 
disorder co-morbidity, a large trial that compared the effectiveness of lithium and 
valproate compared to lithium alone failed due to lack of adherence and non-
response to acute treatment (18). Lamotrigine has been found to improve the 
amount spent on cocaine but not mood scores in people with bipolar disorder and 
cocaine dependence (19) and, in a small RCT, lithium has been found to be effective 
in reducing gambling behaviour and mood instability in pathological gamblers with 
bipolar disorder (20).  
 
There are surprisingly few studies of the effectiveness of antipsychotic medication in 
people with bipolar disorder and co-morbid addictions. Those studies that are 
available have examined the effectiveness of adding quetiapine to mood stabilizers 
for alcohol use disorder co-morbidity and have shown that it is largely ineffective in 
improving either alcohol consumption or mood measures (21, 22). Two small pilot 
RCTs have investigated the effectiveness of adjunctive acamprosate or naltrexone in 
alcohol dependent people with bipolar disorder. Neither found improvements in 
alcohol consumption or mood scores (23, 24), although naltrexone was associated at 
a trend significance level with fewer drinking days and lower craving scores, and 
both medications were safe, well-tolerated and did not destabilize mood. Naltrexone 
is recommended by the British Association for Psychopharmacology treatment 
guidelines to help people with bipolar disorder to reduce their alcohol consumption 
and acamprosate is then recommended if naltrexone has not been effective in 
supporting abstinence (15).  
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Limitations 
 
There are several limitations which constrain our understanding of addiction co-
morbidity in bipolar disorder and how best to provide treatment. Most of the 
prevalence data originates from developed countries, particularly the USA, and there 
is a real need for co-morbidity prevalence data from developing countries. Given the 
importance of addictions in bipolar disorder, there are also surprisingly few studies 
which have investigated neurobiological mechanisms which mediate addictions co-
morbidity. There have also been few well powered RCTs which have investigated 
the effectiveness of pharmacological treatments for bipolar disorder with addiction 
co-morbidity and the lack of an evidence base is a real challenge in determining best 
treatment practice. 
 
Conclusions 
 
Addictions are highly prevalent in bipolar disorder and impact on clinical outcomes 
and risk profiles. The reasons why people with bipolar disorder are at high risk of 
addiction remain unknown and require further investigation but may be mediated by 
shared neurobiological mechanisms. Treating addictions in bipolar disorder requires 
an inclusive, comprehensive approach which supports the identification of addiction 
co-morbidity in bipolar disorder and the development of care plans to minimize risks. 
There is an urgent need for well powered placebo controlled RCTs in this area and, 
as addictions are so prevalent in bipolar disorder, we suggest that excluding people 
with bipolar disorder with a history of addictions from clinical trials significantly limits 
the generalizability of findings to the ‘real life’ bipolar disorder population.  
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